KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Marina A Parry, Emily Grist, Larissa Mendes, Peter Dutey-Magni, Ashwin Sachdeva, Christopher Brawley, Laura Murphy, James Proudfoot, Sharanpreet Lall, Yang Liu, Stefanie Friedrich, Mazlina Ismail, Alex Hoyle, Adnan Ali, Aine Haran, Anna Wingate, Leila Zakka, Daniel Wetterskog, Claire L Amos, Nafisah B Atako, Victoria Wang, Hannah L Rush, Robert J Jones, Hing Leung, William R Cross, Silke Gillessen, Chris C Parker, Simon Chowdhury, STAMPEDE collaborators, Tamara Lotan, Teresa Marafioti, Alfonso Urbanucci, Edward M Schaeffer, Daniel E Spratt, David Waugh, Thomas Powles, Daniel M Berney, Matthew R Sydes, Mahesh K B Parmar, Anis A Hamid, Felix Y Feng, Christopher J Sweeney, Elai Davicioni, Noel W Clarke, Nicholas D James, Louise C Brown, Gerhardt Attard

Res Sq rs.3.rs-2488586

PMID36798177
PMCIDPMC9934744
DOI10.21203/rs.3.rs-2488586/v1
发表日期2023-02-17
摘要

摘要

Metastatic and high-risk localized prostate cancer respond to hormone therapy but outcomes vary. Following a pre-specified statistical plan, we used Cox models adjusted for clinical variables to test associations with survival of multi-gene expression-based classifiers from 781 patients randomized to androgen deprivation with or without abiraterone in the STAMPEDE trial. Decipher score was strongly prognostic (p<2×10-5) and identified clinically-relevant differences in absolute benefit, especially for localized cancers. In metastatic disease, classifiers of proliferation, PTEN or TP53 loss and treatment-persistent cells were prognostic. In localized disease, androgen receptor activity was protective whilst interferon signaling (that strongly associated with tumor lymphocyte infiltration) was detrimental. Post-Operative Radiation-Therapy Outcomes Score was prognostic in localized but not metastatic disease (interaction p=0.0001) suggesting the impact of tumor biology on clinical outcome is context-dependent on metastatic state. Transcriptome-wide testing has clinical utility for advanced prostate cancer and identified worse outcomes for localized cancers with tumor-promoting inflammation.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。